Vol 70, No 6 (2019)
Original paper
Published online: 2019-09-17

open access

Page views 2064
Article views/downloads 1156
Get Citation

Connect on Social Media

Connect on Social Media

Is ultrasound combined with computed tomography useful for distinguishing between primary thyroid lymphoma and Hashimoto’s thyroiditis?

Jieli Luo1, Fengbo Huang2, Panpan Zhou3, Jianshe Chen1, Yang Sun1, Fangting Xu1, Lilu Wu1, Pintong Huang1
Pubmed: 31529457
Endokrynol Pol 2019;70(6):463-468.


Introduction: The aim of the study is to investigate the usefulness of ultrasound combined with computed tomography (CT) for distinguishing between primary thyroid lymphoma (PTL) and Hashimoto’s thyroiditis (HT). Material and methods: The investigation was conducted retrospectively in 80 patients from January 2000 to July 2018. All patients underwent pathological tests to be classified into one of two groups: PTL group and HT group. The cut-off value of CT density was determined using receiver-operating characteristic (ROC) curve analysis. The accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of diagnosis for thyroid by CT alone, ultrasound alone, and the combination of CT plus ultrasound were calculated. Results: Of the 80 study patients, 27 patients were PTL and 53 patients were HT. Mean CT density had a sensitivity of 90.6% and a specificity of 88.9% at a cut-off value of 53.5 HU, with area under the curve (AUC) 0.88. Ultrasound combined with CT had the highest specificity, accuracy, and PPV compared with CT alone and ultrasound alone (p value < 0.05). Conclusions: Features such as extremely hypoechogenicity, enhanced posterior echo, cervical lymphadenopathy in ultrasound image, and linear high-density strand signs, and very low density in CT imaging have high sensitivity and specificity in thyroid lymphoma. Therefore, ultrasound combined with CT may be useful for distinguishing between PTL and HT. 

Article available in PDF format

View PDF Download PDF file


  1. Perez-Cornago A, Appleby PN, Tipper S, et al. Prediagnostic circulating concentrations of plasma insulin-like growth factor-I and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2017; 140(5): 1111–1118.
  2. Borrelli N, Denaro M, Ugolini C, et al. miRNA expression profiling of 'noninvasive follicular thyroid neoplasms with papillary-like nuclear features' compared with adenomas and infiltrative follicular variants of papillary thyroid carcinomas. Mod Pathol. 2017; 30(1): 39–51.
  3. Falduto A, Cimino F, Speciale A, et al. How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma. Blood Rev. 2017; 31(4): 235–249.
  4. Karmali R, Nabhan C, Petrich AM, et al. Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma. Br J Haematol. 2017; 177(1): 72–79.
  5. Hude I, Sasse S, Engert A, et al. The emerging role of immune checkpoint inhibition in malignant lymphoma. Haematologica. 2017; 102(1): 30–42.
  6. Vater I, Montesinos-Rongen M, Schlesner M, et al. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia. 2015; 29(3): 677–685.
  7. Adams HJA, Kwee TC. Critical considerations on the predictive value of end-of-treatment FDG-PET in lymphoma. Eur J Nucl Med Mol Imaging. 2017; 44(2): 342–343.
  8. Carbone A, Gloghini A, Caruso A, et al. The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis. Int J Cancer. 2017; 140(6): 1233–1245.
  9. Burns A, Alsolami R, Becq J, et al. Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV and IgHV subgroups. Leukemia. 2018; 32(2): 332–342.
  10. Zaghlol RY, Haghighi A, Alkhayyat MM, et al. Consanguinity and the Risk of Hashimoto's Thyroiditis. Thyroid. 2017; 27(3): 390–395.
  11. Hu S, Rayman MP. Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis. Thyroid. 2017; 27(5): 597–610.
  12. Perga S, Martire S, Montarolo F, et al. The Footprints of Poly-Autoimmunity: Evidence for Common Biological Factors Involved in Multiple Sclerosis and Hashimoto's Thyroiditis. Front Immunol. 2018; 9: 311.
  13. Barrantes-Freer A, Engel AS, Rodriguez-Villagra OA, et al. Diagnostic red flags: steroid-treated malignant CNS lymphoma mimicking autoimmune inflammatory demyelination. Brain Pathol. 2018; 28(2): 225–233.
  14. Huang Yu, Jia Bo, Jiang S, et al. Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma. J Hematol Oncol. 2017; 10(1): 7.
  15. Mihara K, Yoshida T, Takei Y, et al. T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells. J Hematol Oncol. 2017; 10(1): 116.
  16. England CG, Rui L, Cai W. Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies. Eur J Nucl Med Mol Imaging. 2017; 44(3): 517–532.
  17. Chang Yu, Cui M, Fu X, et al. MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1. Cancer Biol Ther. 2019; 20(1): 31–41.
  18. Lubitz CC, De Gregorio L, Fingeret AL, et al. Measurement and Variation in Estimation of Quality of Life Effects of Patients Undergoing Treatment for Papillary Thyroid Carcinoma. Thyroid. 2017; 27(2): 197–206.
  19. Mathur R, Sehgal L, Havranek O, et al. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica. 2017; 102(2): 373–380.
  20. Redaelli S, Ceccon M, Antolini L, et al. Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma. Oncotarget. 2016; 7(45): 72886–72897.
  21. Schuhmacher B, Bein J, Rausch T, et al. et al.. JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte rich large B-cell lymphoma. Haematologica. 2019; 104(2): 330–337.
  22. Marotta V, Sciammarella C, Chiofalo MG, et al. Hashimoto's thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer. Endocr Relat Cancer. 2017; 24(9): 485–493.
  23. Arcolia V, Journe F, Wattier A, et al. Galectin-1 is a diagnostic marker involved in thyroid cancer progression. Int J Oncol. 2017; 51(3): 760–770.
  24. Ha EJu, Na DG, Baek JH, et al. US Fine-Needle Aspiration Biopsy for Thyroid Malignancy: Diagnostic Performance of Seven Society Guidelines Applied to 2000 Thyroid Nodules. Radiology. 2018; 287(3): 893–900.
  25. Haymart MR, Banerjee M, Reyes-Gastelum D, et al. Thyroid Ultrasound and the Increase in Diagnosis of Low-Risk Thyroid Cancer. J Clin Endocrinol Metab. 2019; 104(3): 785–792.
  26. Hoang JK, Middleton WD, Farjat AE, et al. Reduction in Thyroid Nodule Biopsies and Improved Accuracy with American College of Radiology Thyroid Imaging Reporting and Data System. Radiology. 2018; 287(1): 185–193.
  27. Kim M, Kim WG, Oh HS, et al. Comparison of the Seventh and Eighth Editions of the American Joint Committee on Cancer/Union for International Cancer Control Tumor-Node-Metastasis Staging System for Differentiated Thyroid Cancer. Thyroid. 2017; 27(9): 1149–1155.
  28. Sharma A, Jasim S, Reading CC, et al. Clinical Presentation and Diagnostic Challenges of Thyroid Lymphoma: A Cohort Study. Thyroid. 2016; 26(8): 1061–1067.
  29. Clement SC, Kremer LCM, Verburg FA, et al. Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent and young adult cancer: Recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Cancer Treat Rev. 2018; 63: 28–39.
  30. Lauria Pantano A, Maddaloni E, Briganti SI, et al. Differences between ATA, AACE/ACE/AME and ACR TI-RADS ultrasound classifications performance in identifying cytological high-risk thyroid nodules. Eur J Endocrinol. 2018; 178(6): 595–603.
  31. Persichetti A, Di Stasio E, Guglielmi R, et al. Predictive Value of Malignancy of Thyroid Nodule Ultrasound Classification Systems: A Prospective Study. J Clin Endocrinol Metab. 2018; 103(4): 1359–1368.
  32. Monteiro R, Han A, Etiwy M, et al. Importance of surgeon-performed ultrasound in the preoperative nodal assessment of patients with potential thyroid malignancy. Surgery. 2018; 163(1): 112–117.
  33. Freesmeyer M, Winkens T, Kuehnel C, et al. 99mTc-Pertechnetate-SPECT/US Hybrid Imaging Enhances Diagnostic Certainty Compared With Conventional Thyroid Imaging With Scintigraphy and Ultrasound. Clin Nucl Med. 2018; 43(10): 747–748.
  34. Bulanova EA, Koudan EV, Degosserie J, et al. Bioprinting of a functional vascularized mouse thyroid gland construct. Biofabrication. 2017; 9(3): 034105.
  35. Yoo J, Ahn HS, Kim SJ, et al. Evaluation of Diagnostic Performance of Screening Thyroid Ultrasonography and Imaging Findings of Screening-Detected Thyroid Cancer. Cancer Res Treat. 2018; 50(1): 11–18.
  36. Symonds CJ, Seal P, Ghaznavi S, et al. Thyroid nodule ultrasound reports in routine clinical practice provide insufficient information to estimate risk of malignancy. Endocrine. 2018; 61(2): 303–307.
  37. Sterle HA, Barreiro Arcos ML, Valli E, et al. The thyroid status reprograms T cell lymphoma growth and modulates immune cell frequencies. J Mol Med (Berl). 2016; 94(4): 417–429.
  38. Lollert A, Gies C, Laudemann K, et al. Ultrasound Evaluation of Thyroid Gland Pathologies After Radiation Therapy and Chemotherapy to Treat Malignancy During Childhood. Int J Radiat Oncol Biol Phys. 2016; 94(1): 139–146.
  39. Orita Y, Sato Y, Kimura N, et al. Characteristic ultrasound features of mucosa-associated lymphoid tissue lymphoma of the salivary and thyroid gland. Acta Otolaryngol. 2014; 134(1): 93–99.
  40. Liao J, Luan Y, Ren Z, et al. Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression. Cancer Immunol Res. 2017; 5(7): 560–570.
  41. Gupta NK, Nolan A, Omuro A, et al. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro Oncol. 2017; 19(1): 99–108.